Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

RedHill Biopharma has said it intends "to request a pre-NDA meeting with the FDA in the coming weeks to discuss a US NDA marketing approval application for RHB-102", its once-daily controlled release formulation of the antiemetic, ondansetron, for the prevention of nausea and vomiting in cancer patients.

GOGO reformulates Purell sanitizer; Life Extension brews up glucose support supplement; AllergEase allergy lozenges out in time for spring; Cardia 7 claims “heartier omega” mantle; extended-release SCOLR supplements debut; Tom’s of Maine rolls out natural antiperspirant; more New Products In Brief.